Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Income towards Parent Company: 2013-2024

Historic Income towards Parent Company for Soleno Therapeutics (SLNO) over the last 9 years, with Dec 2024 value amounting to -$175.8 million.

  • Soleno Therapeutics' Income towards Parent Company rose 54.35% to -$544,000 in Q4 2017 from the same period last year, while for Dec 2017 it was -$3.6 million, marking a year-over-year increase of 52.99%. This contributed to the annual value of -$175.8 million for FY2024, which is 353.15% down from last year.
  • Soleno Therapeutics' Income towards Parent Company amounted to -$175.8 million in FY2024, which was down 353.15% from -$38.8 million recorded in FY2023.
  • Soleno Therapeutics' 5-year Income towards Parent Company high stood at -$24.1 million for FY2022, and its period low was -$175.8 million during FY2024.
  • Over the past 3 years, Soleno Therapeutics' median Income towards Parent Company value was -$38.8 million (recorded in 2023), while the average stood at -$79.6 million.
  • Data for Soleno Therapeutics' Income towards Parent Company shows a maximum YoY slumped of 353.15% (in 2024) over the last 5 years.
  • Over the past 3 years, Soleno Therapeutics' Income towards Parent Company (Yearly) stood at -$24.1 million in 2022, then tumbled by 61.04% to -$38.8 million in 2023, then tumbled by 353.15% to -$175.8 million in 2024.